Amarin Corporation plc (AMRN)
USD 0.4
(0.32%)
USD 0.4
(0.32%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 272.35 Million USD | -34.28% |
| 2022 | 334.82 Million USD | -23.49% |
| 2021 | 437.64 Million USD | -12.87% |
| 2020 | 502.27 Million USD | 40.29% |
| 2019 | 358.01 Million USD | 26.55% |
| 2018 | 282.89 Million USD | 55.69% |
| 2017 | 181.7 Million USD | 12.62% |
| 2016 | 161.34 Million USD | 6.08% |
| 2015 | 152.1 Million USD | 17.3% |
| 2014 | 129.67 Million USD | -33.16% |
| 2013 | 193.99 Million USD | 66.16% |
| 2012 | 116.75 Million USD | 164.37% |
| 2011 | 44.16 Million USD | -2.08% |
| 2010 | 45.1 Million USD | 45.82% |
| 2009 | 30.92 Million USD | 9.76% |
| 2008 | 28.18 Million USD | -30.82% |
| 2007 | 40.73 Million USD | 30.85% |
| 2006 | 31.13 Million USD | 65.97% |
| 2005 | 18.75 Million USD | 56.27% |
| 2004 | 12 Million USD | -64.98% |
| 2003 | 34.27 Million USD | -50.41% |
| 2002 | 69.11 Million USD | 84.83% |
| 2001 | 37.39 Million USD | 151.11% |
| 2000 | 14.89 Million USD | -1.06% |
| 1999 | 15.05 Million USD | -53.11% |
| 1998 | 32.1 Million USD | 8.45% |
| 1997 | 29.6 Million USD | -17.32% |
| 1996 | 35.8 Million USD | 82.65% |
| 1995 | 19.6 Million USD | 0.0% |
| 1994 | - USD | -100.0% |
| 1993 | 10.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 41.44 Million USD | -2.67% |
| 2024 Q2 | 42.57 Million USD | -4.74% |
| 2024 Q1 | 44.69 Million USD | -9.56% |
| 2023 Q4 | 49.42 Million USD | -2.25% |
| 2023 Q2 | 56.59 Million USD | -13.29% |
| 2023 FY | 220.04 Million USD | -34.28% |
| 2023 Q3 | 50.56 Million USD | -10.66% |
| 2023 Q1 | 65.26 Million USD | -11.04% |
| 2022 Q1 | 100.69 Million USD | 2.63% |
| 2022 Q2 | 96.24 Million USD | -4.42% |
| 2022 Q4 | 73.37 Million USD | 13.73% |
| 2022 FY | 334.82 Million USD | -23.49% |
| 2022 Q3 | 64.51 Million USD | -32.98% |
| 2021 FY | 437.64 Million USD | -12.87% |
| 2021 Q3 | 110.78 Million USD | -2.44% |
| 2021 Q1 | 115.17 Million USD | -8.1% |
| 2021 Q2 | 113.56 Million USD | -1.4% |
| 2021 Q4 | 98.12 Million USD | -11.43% |
| 2020 Q4 | 125.32 Million USD | -3.87% |
| 2020 FY | 502.27 Million USD | 40.29% |
| 2020 Q3 | 130.36 Million USD | 27.36% |
| 2020 Q2 | 102.36 Million USD | -29.02% |
| 2020 Q1 | 144.21 Million USD | 34.63% |
| 2019 FY | 358.01 Million USD | 26.55% |
| 2019 Q4 | 107.12 Million USD | 17.1% |
| 2019 Q3 | 91.48 Million USD | 13.59% |
| 2019 Q2 | 80.53 Million USD | 2.11% |
| 2019 Q1 | 78.87 Million USD | -13.88% |
| 2018 Q4 | 91.59 Million USD | 43.04% |
| 2018 FY | 282.89 Million USD | 55.69% |
| 2018 Q1 | 55.16 Million USD | 15.94% |
| 2018 Q2 | 72.1 Million USD | 30.69% |
| 2018 Q3 | 64.03 Million USD | -11.19% |
| 2017 Q3 | 43.88 Million USD | -2.99% |
| 2017 Q2 | 45.23 Million USD | 0.54% |
| 2017 FY | 181.7 Million USD | 12.62% |
| 2017 Q1 | 44.99 Million USD | 8.68% |
| 2017 Q4 | 47.58 Million USD | 8.43% |
| 2016 Q4 | 41.4 Million USD | 4.68% |
| 2016 Q3 | 39.55 Million USD | 2.35% |
| 2016 Q2 | 38.64 Million USD | -7.44% |
| 2016 Q1 | 41.75 Million USD | 13.25% |
| 2016 FY | 161.34 Million USD | 6.08% |
| 2015 Q2 | 38.06 Million USD | 1.9% |
| 2015 Q4 | 36.86 Million USD | -7.42% |
| 2015 Q3 | 39.81 Million USD | 4.61% |
| 2015 Q1 | 37.35 Million USD | 21.16% |
| 2015 FY | 152.1 Million USD | 17.3% |
| 2014 FY | 129.67 Million USD | -33.16% |
| 2014 Q1 | 32.29 Million USD | -11.15% |
| 2014 Q3 | 33.72 Million USD | 2.76% |
| 2014 Q2 | 32.82 Million USD | 1.64% |
| 2014 Q4 | 30.83 Million USD | -8.58% |
| 2013 Q1 | 61.1 Million USD | 69.94% |
| 2013 FY | 193.99 Million USD | 66.16% |
| 2013 Q3 | 45.09 Million USD | -12.35% |
| 2013 Q4 | 36.34 Million USD | -19.4% |
| 2013 Q2 | 51.45 Million USD | -15.8% |
| 2012 Q1 | 18.78 Million USD | 52.4% |
| 2012 FY | 116.75 Million USD | 164.37% |
| 2012 Q4 | 35.95 Million USD | 4.8% |
| 2012 Q3 | 34.31 Million USD | 23.86% |
| 2012 Q2 | 27.7 Million USD | 47.48% |
| 2011 Q3 | 9.44 Million USD | -37.91% |
| 2011 Q4 | 12.32 Million USD | 30.48% |
| 2011 Q1 | 7.17 Million USD | -58.6% |
| 2011 FY | 44.16 Million USD | -2.08% |
| 2011 Q2 | 15.21 Million USD | 112.04% |
| 2010 Q2 | 10.58 Million USD | 43.0% |
| 2010 Q4 | 17.33 Million USD | 77.28% |
| 2010 Q1 | 7.4 Million USD | 0.0% |
| 2010 FY | 45.1 Million USD | 45.82% |
| 2010 Q3 | 9.77 Million USD | -7.68% |
| 2009 FY | 30.92 Million USD | 9.76% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q1 | 7.82 Million USD | 1.24% |
| 2008 FY | 28.18 Million USD | -30.82% |
| 2008 Q2 | -6.74 Million USD | -186.21% |
| 2007 Q3 | 6.89 Million USD | -58.08% |
| 2007 Q4 | 7.73 Million USD | 12.24% |
| 2007 FY | 40.73 Million USD | 30.85% |
| 2007 Q2 | 16.43 Million USD | 69.93% |
| 2007 Q1 | 9.67 Million USD | 12.71% |
| 2006 Q3 | 8.35 Million USD | 5.19% |
| 2006 Q1 | 6.24 Million USD | 133.3% |
| 2006 Q4 | 8.58 Million USD | 2.69% |
| 2006 FY | 31.13 Million USD | 65.97% |
| 2006 Q2 | 7.94 Million USD | 27.2% |
| 2005 Q1 | -3.39 Million USD | -137.46% |
| 2005 FY | 18.75 Million USD | 56.27% |
| 2005 Q3 | - USD | -100.0% |
| 2005 Q4 | -18.75 Million USD | 0.0% |
| 2005 Q2 | 5.67 Million USD | 266.86% |
| 2004 Q3 | 1.26 Million USD | -59.38% |
| 2004 Q4 | 9.07 Million USD | 619.27% |
| 2004 Q1 | - USD | -100.0% |
| 2004 Q2 | 3.1 Million USD | 0.0% |
| 2004 FY | 12 Million USD | -64.98% |
| 2003 Q3 | 3.79 Million USD | -54.33% |
| 2003 Q1 | - USD | 100.0% |
| 2003 Q2 | 8.3 Million USD | 0.0% |
| 2003 FY | 34.27 Million USD | -50.41% |
| 2003 Q4 | 24.46 Million USD | 544.77% |
| 2002 Q4 | -99.24 Million USD | 0.0% |
| 2002 Q3 | - USD | -100.0% |
| 2002 Q2 | 2.51 Million USD | 0.0% |
| 2002 Q1 | - USD | -100.0% |
| 2002 FY | 69.11 Million USD | 84.83% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q4 | 25.68 Million USD | 0.0% |
| 2001 FY | 37.39 Million USD | 151.11% |
| 2001 Q1 | - USD | 100.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | -20.11 Million USD | 0.0% |
| 2000 FY | 14.89 Million USD | -1.06% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | 15.05 Million USD | -53.11% |
| 1999 Q2 | - USD | 0.0% |
| 1998 Q3 | -35.8 Million USD | 0.0% |
| 1998 FY | 32.1 Million USD | 8.45% |
| 1998 Q4 | - USD | 100.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 FY | 29.6 Million USD | -17.32% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q4 | - USD | 100.0% |
| 1997 Q3 | -32.4 Million USD | 0.0% |
| 1996 Q3 | -39.8 Million USD | 0.0% |
| 1996 FY | 35.8 Million USD | 82.65% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q4 | - USD | 100.0% |
| 1996 Q2 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q3 | -24.5 Million USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 FY | 19.6 Million USD | 0.0% |
| 1995 Q4 | - USD | 100.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 FY | - USD | -100.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 FY | 10.5 Million USD | 0.0% |
| 1993 Q4 | - USD | 100.0% |
| 1993 Q3 | -13.6 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 1.045% |
| Alkermes plc | 996.24 Million USD | 72.662% |
| Agenus Inc. | 78.18 Million USD | -248.358% |
| Aptorum Group Limited | 10.56 Thousand USD | -2577573.67% |
| Ardelyx, Inc. | 169.93 Million USD | -60.269% |
| Dyadic International, Inc. | 9.15 Million USD | -2875.702% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1123.911% |
| Lantern Pharma Inc. | 17.87 Million USD | -1423.456% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -3945.741% |
| Novavax, Inc. | 779.12 Million USD | 65.043% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -235.986% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -231.351% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1302.563% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -819.939% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -412.659% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 28.421% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1020.506% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -619.208% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -785.109% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -221.494% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1460.159% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -61.698% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -732.514% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -70.45% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 84.87% |
| AlloVir, Inc. | 180.93 Million USD | -50.529% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 38.897% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -817.583% |
| Bicycle Therapeutics plc | 216.92 Million USD | -25.555% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -58.437% |
| ChromaDex Corporation | 56.37 Million USD | -383.082% |
| Chimerix, Inc. | 93.38 Million USD | -191.637% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1858.045% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -80.925% |
| CRISPR Therapeutics AG | 463.49 Million USD | 41.238% |
| Precision BioSciences, Inc. | 92.46 Million USD | -194.558% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -7.209% |
| Fortress Biotech, Inc. | 200.19 Million USD | -36.046% |
| Fortress Biotech, Inc. | 200.19 Million USD | -36.046% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -731.726% |
| ImmuCell Corporation | 9.61 Million USD | -2731.93% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -72.581% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1587.35% |
| Incyte Corporation | 1.19 Billion USD | 77.122% |
| Innoviva, Inc. | 132.15 Million USD | -106.091% |
| IO Biotech, Inc. | 91.44 Million USD | -197.843% |
| Jaguar Health, Inc. | 42.01 Million USD | -548.238% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -60.894% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -222.993% |
| ContextLogic Inc. | 387 Million USD | 29.624% |
| MiMedx Group, Inc. | 229.72 Million USD | -18.557% |
| MEI Pharma, Inc. | 34.78 Million USD | -682.973% |
| NextCure, Inc. | 67.63 Million USD | -302.675% |
| Onconetix, Inc. | 34.9 Million USD | -680.226% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -2036.804% |
| Opthea Limited | 191.96 Million USD | -41.877% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -9798.186% |
| Vaxcyte, Inc. | 468.04 Million USD | 41.809% |
| PDS Biotechnology Corporation | 43.04 Million USD | -532.723% |
| Precigen, Inc. | 84.18 Million USD | -223.537% |
| Pharming Group N.V. | 225.49 Million USD | -20.784% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -62.284% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -275.323% |
| PureTech Health plc | 144.59 Million USD | -88.356% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -109.082% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -11.094% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1020.506% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -19.1% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -782.585% |
| Acelyrin, Inc. | 422.06 Million USD | 35.47% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -2112177.028% |
| Summit Therapeutics Inc. | 87.68 Million USD | -210.605% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -634.829% |
| Senti Biosciences, Inc. | 94.7 Million USD | -187.585% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -120.437% |
| Elevation Oncology, Inc. | 45.44 Million USD | -499.311% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -824.215% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -6809.023% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -106.058% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -699.052% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -3122.778% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -50.224% |
| Seer, Inc. | 110.49 Million USD | -146.499% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -285.808% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -191.359% |
| ESSA Pharma Inc. | 32.13 Million USD | -747.564% |
| GlycoMimetics, Inc. | 39.28 Million USD | -593.28% |
| GT Biopharma, Inc. | 13.57 Million USD | -1906.165% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -23.894% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -35.424% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -4.985% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -379.848% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -403.619% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -2640.659% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 32.512% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -1338.835% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -437.267% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -4.89% |
| Aptose Biosciences Inc. | 52.35 Million USD | -420.202% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1790.006% |
| Soligenix, Inc. | 7.79 Million USD | -3393.884% |
| Century Therapeutics, Inc. | 56.07 Million USD | -385.736% |
| Kura Oncology, Inc. | 165.8 Million USD | -64.264% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -137.852% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -3173.915% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -10874.884% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -152.89% |
| Autolus Therapeutics plc | 196.72 Million USD | -38.445% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -221.718% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -133.877% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1305.133% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 15.353% |
| GRI Bio, Inc. | 11.33 Million USD | -2303.857% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -3760.098% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -107.6% |
| IGM Biosciences, Inc. | 265.59 Million USD | -2.548% |
| INmune Bio, Inc. | 29.89 Million USD | -811.015% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -57.839% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -575.584% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1604.43% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1630.179% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -338.592% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -153.304% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 1.21% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 9.651% |
| Verastem, Inc. | 92.08 Million USD | -195.77% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1418.24% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -46.645% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -124.334% |
| Histogen Inc. | 14.27 Million USD | -1808.331% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1597.125% |
| Surrozen, Inc. | 18.55 Million USD | -1368.232% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1726.061% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -5250.577% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -356.415% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -961.945% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -479.409% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -3468.225% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -52.893% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -462.164% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -11.164% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1672.399% |
| Apollomics, Inc. | 54.14 Million USD | -403.061% |
| Mesoblast Limited | 5.9 Million USD | -4514.656% |
| Turnstone Biologics Corp. | 78.33 Million USD | -247.669% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -11.566% |
| Synaptogenix, Inc. | 8.31 Million USD | -3175.942% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1767.249% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -7.627% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -717.151% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2984.019% |
| Exelixis, Inc. | 1.58 Billion USD | 82.836% |
| Better Therapeutics, Inc. | 38.26 Million USD | -611.821% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -17.37% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 68.153% |
| NLS Pharmaceutics AG | 11.8 Million USD | -2206.729% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -3286.722% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -808.069% |
| Gritstone bio, Inc. | 148.37 Million USD | -83.561% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -295.517% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1564.752% |
| Avid Bioservices, Inc. | 25.99 Million USD | -947.688% |
| Insmed Incorporated | 949.26 Million USD | 71.309% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1635.887% |
| MediWound Ltd. | 18.86 Million USD | -1343.486% |
| OmniAb, Inc. | 83.89 Million USD | -224.64% |
| Alector, Inc. | 248.8 Million USD | -9.467% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -16.239% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -421.247% |
| Zai Lab Limited | 547.47 Million USD | 50.252% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 31.681% |
| Aura Biosciences, Inc. | 84.99 Million USD | -220.454% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -10.204% |
| Immunic, Inc. | 99.22 Million USD | -174.49% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -71.281% |
| Veracyte, Inc. | 357.93 Million USD | 23.908% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 96.979% |
| FibroGen, Inc. | 398.11 Million USD | 31.588% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1816.657% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -3854.11% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -3722.162% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 91.634% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -952.669% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 13.959% |
| TG Therapeutics, Inc. | 198.47 Million USD | -37.225% |
| Galecto, Inc. | 35.62 Million USD | -664.468% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -569.363% |
| Fortrea Holdings Inc. | 457.3 Million USD | 40.442% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -401.782% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -843.13% |
| XBiotech Inc. | 37.51 Million USD | -626.092% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -295.517% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1218.984% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -91.718% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -174.9% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -145.996% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 71.578% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -844.209% |
| Vaxxinity, Inc. | 56.05 Million USD | -385.909% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 36.755% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1120.877% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -145.661% |
| NexImmune, Inc. | 28.16 Million USD | -866.919% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -4824.237% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1422.184% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 90.326% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -969.787% |
| Scopus BioPharma Inc. | 11.71 Million USD | -2224.881% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -114.35% |
| Ainos, Inc. | 12.95 Million USD | -2002.71% |
| Pluri Inc. | 22.48 Million USD | -1111.552% |
| Prothena Corporation plc | 282.4 Million USD | 3.558% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -36.164% |
| Celularity Inc. | 215.05 Million USD | -26.644% |
| Rallybio Corporation | 78.93 Million USD | -245.053% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1293.701% |
| MeiraGTx Holdings plc | 151.07 Million USD | -80.276% |
| Omeros Corporation | 94.75 Million USD | -187.445% |
| Humacyte, Inc. | 23.49 Million USD | -1059.114% |
| Immunocore Holdings plc | 308.04 Million USD | 11.584% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -7934.13% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -213.541% |
| Blueprint Medicines Corporation | 722.86 Million USD | 62.322% |
| CalciMedica, Inc. | 21.81 Million USD | -1148.371% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -264.796% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -69.651% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -58.999% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 7.657% |
| Pulmatrix, Inc. | 22.03 Million USD | -1135.852% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -687.728% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -206.481% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 50.621% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -275.401% |
| Cytokinetics, Incorporated | 173.61 Million USD | -56.877% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -691.298% |
| Nutriband Inc. | 5.73 Million USD | -4649.835% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -524.486% |
| Vor Biopharma Inc. | 126.03 Million USD | -116.095% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 77.097% |
| Evogene Ltd. | 27.79 Million USD | -880.054% |
| ProKidney Corp. | 151.52 Million USD | -79.747% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -267.182% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -3440.671% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 55.659% |
| CorMedix Inc. | 48.95 Million USD | -456.31% |
| BioLineRx Ltd. | 50.8 Million USD | -436.115% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -80.728% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -615.374% |
| Atai Life Sciences N.V. | 125.78 Million USD | -116.526% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -233.61% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -234.554% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -7.842% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -731.878% |
| MediciNova, Inc. | 10.9 Million USD | -2398.627% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -111.424% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3651.72% |
| GeoVax Labs, Inc. | 6.02 Million USD | -4422.57% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 42.825% |
| Biomea Fusion, Inc. | 126.13 Million USD | -115.925% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 79.239% |
| Mereo BioPharma Group plc | 35.84 Million USD | -659.882% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -42.529% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -18.44% |
| Absci Corporation | 73.66 Million USD | -269.719% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -887.445% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -103.875% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -12.469% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -3.934% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -30.945% |
| Allakos Inc. | 196.05 Million USD | -38.918% |
| Imunon, Inc. | 20.31 Million USD | -1240.971% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -140.028% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 26.113% |
| BioAtla, Inc. | 129.68 Million USD | -110.011% |
| NLS Pharmaceutics AG | 11.8 Million USD | -2206.729% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1619.1% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -220.729% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -552.227% |
| XOMA Corporation | 46.46 Million USD | -486.18% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -144.989% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -91.177% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1998.444% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -162.751% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -57.55% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -6.906% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -628.072% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -3211.406% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1520.594% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -11877.159% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 9.007% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3947.673% |
| UroGen Pharma Ltd. | 138.88 Million USD | -96.098% |
| Sutro Biopharma, Inc. | 243 Million USD | -12.077% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -3643.933% |
| Orgenesis Inc. | 45.75 Million USD | -495.225% |
| Entera Bio Ltd. | 8.86 Million USD | -2974.007% |
| GH Research PLC | 41.22 Million USD | -560.708% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -959.425% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -227.932% |
| Xencor, Inc. | 306.97 Million USD | 11.278% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -5420.445% |
| Replimune Group, Inc. | 234.77 Million USD | -16.009% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1229.226% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -42.003% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3947.673% |
| Portage Biotech Inc. | 18.19 Million USD | -1396.549% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3651.72% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -159.484% |
| OncoCyte Corporation | 25.63 Million USD | -962.359% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -4368.087% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -2277.198% |
| Purple Biotech Ltd. | -22.46 Million USD | 1312.254% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1552.652% |
| scPharmaceuticals Inc. | 65.17 Million USD | -317.866% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -3122.116% |
| HilleVax, Inc. | 133.34 Million USD | -104.25% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -2548.099% |
| Tharimmune, Inc. | 9.45 Million USD | -2780.494% |
| Genprex, Inc. | 31.06 Million USD | -776.858% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -45.237% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -768.015% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -35502.222% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -4900.203% |
| OKYO Pharma Limited | 8243.57 USD | -3303771.988% |
| Savara Inc. | 15.74 Million USD | -1629.8% |
| Curis, Inc. | 58.35 Million USD | -366.724% |
| Daré Bioscience, Inc. | 33.6 Million USD | -710.36% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -5248.211% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -3550.409% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -907.908% |
| BeiGene, Ltd. | 3.28 Billion USD | 91.713% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -1265.931% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 45.394% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -77.256% |
| Erasca, Inc. | 141.52 Million USD | -92.444% |
| bluebird bio, Inc. | 240.23 Million USD | -13.372% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -5916.315% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 84.404% |
| DBV Technologies S.A. | 92.16 Million USD | -195.526% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -5916.315% |
| Moderna, Inc. | 6.39 Billion USD | 95.74% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -539.201% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1795.844% |
| Molecular Templates, Inc. | 63.09 Million USD | -331.689% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -308.325% |
| Travere Therapeutics, Inc. | 472 Million USD | 42.297% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -90.046% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -338.705% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -527.348% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -30.859% |
| MacroGenics, Inc. | 217.21 Million USD | -25.386% |
| RenovoRx, Inc. | 11.39 Million USD | -2289.935% |
| Adicet Bio, Inc. | 152.03 Million USD | -79.137% |
| Prime Medicine, Inc. | 186.63 Million USD | -45.927% |
| Aditxt, Inc. | 25.95 Million USD | -949.514% |
| Adagene Inc. | 41.83 Million USD | -551.083% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3625.764% |
| Quantum-Si incorporated | 111.65 Million USD | -143.919% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -58.485% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1768.304% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -660.307% |
| SciSparc Ltd. | 9.01 Million USD | -2922.495% |
| Vericel Corporation | 142.04 Million USD | -91.747% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -3046.212% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -1079.617% |
| Generation Bio Co. | 144.46 Million USD | -88.525% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -228.022% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -215.009% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 7.9% |
| Invivyd, Inc. | 205.75 Million USD | -32.37% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -277.44% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -2804.056% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -261.917% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -2547.584% |
| 2seventy bio, Inc. | 289.88 Million USD | 6.047% |
| ADMA Biologics, Inc. | 66.58 Million USD | -309.03% |
| Clene Inc. | 41.07 Million USD | -563.105% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -2026.479% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -397.038% |
| GeoVax Labs, Inc. | 6.02 Million USD | -4422.57% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 22.636% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -641.47% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -707.51% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -162.634% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -735.733% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -59.948% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 64.524% |
| Evaxion Biotech A/S | 22.27 Million USD | -1122.977% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -100.936% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -15.955% |
| Trevena, Inc. | 38.41 Million USD | -609.023% |
| Surrozen, Inc. | 18.55 Million USD | -1368.232% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -240.68% |
| Cingulate Inc. | 22.75 Million USD | -1096.69% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 3735.304% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -509.75% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -3207.736% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -165.564% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 63.882% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -338.762% |
| Clearmind Medicine Inc. | 8.74 Million USD | -3015.732% |
| Kronos Bio, Inc. | 128.11 Million USD | -112.583% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -223.957% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -9186.0% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -170.123% |
| Statera Biopharma, Inc. | 28.82 Million USD | -844.716% |
| ImmunityBio, Inc. | 362.87 Million USD | 24.944% |
| Korro Bio, Inc. | 84.53 Million USD | -222.186% |
| Kineta, Inc. | 21.15 Million USD | -1187.375% |
| BioVie Inc. | 31.95 Million USD | -752.442% |
| Codexis, Inc. | 66.51 Million USD | -309.449% |
| Celularity Inc. | 215.05 Million USD | -26.644% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -20.182% |
| Celcuity Inc. | 66.23 Million USD | -311.227% |
| Virax Biolabs Group Limited | 6.54 Million USD | -4059.987% |
| Cibus, Inc. | 320.3 Million USD | 14.969% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -533.388% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -704.742% |
| IN8bio, Inc. | 30.33 Million USD | -797.772% |
| Kodiak Sciences Inc. | 277.32 Million USD | 1.79% |
| Annexon, Inc. | 143.72 Million USD | -89.501% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -113.461% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -1088.865% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -42455.781% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 65.064% |
| Eyenovia, Inc. | 25.4 Million USD | -972.0% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -94.104% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4796.746% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -244.176% |
| Arcellx, Inc. | 200.19 Million USD | -36.043% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -493.37% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -25.852% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -2635.332% |
| Moolec Science SA | 52.75 Million USD | -416.311% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -345.479% |
| Geron Corporation | 70.44 Million USD | -286.646% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -485.211% |
| Royalty Pharma plc | 862.4 Million USD | 68.419% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -189.52% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -2819.821% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -1103.6% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -31.059% |
| Humacyte, Inc. | 23.49 Million USD | -1059.114% |
| Structure Therapeutics Inc. | 102.77 Million USD | -165.003% |
| 89bio, Inc. | 151.2 Million USD | -80.126% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -239.885% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1773.157% |
| Genelux Corporation | 24.33 Million USD | -1019.199% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -702.868% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -57.551% |
| Notable Labs, Ltd. | 14.77 Million USD | -1743.988% |
| Liquidia Corporation | 87.98 Million USD | -209.553% |
| Mustang Bio, Inc. | 48.5 Million USD | -461.549% |
| Immunovant, Inc. | 282.7 Million USD | 3.662% |
| Quantum-Si incorporated | 111.65 Million USD | -143.919% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1108.113% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1180.655% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -166.985% |
| Acasti Pharma Inc. | 11.3 Million USD | -2310.026% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -1088.237% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1604.43% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -485.185% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -23905.094% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1614.447% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -834.105% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -558.121% |
| PepGen Inc. | 84.76 Million USD | -221.305% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -819.162% |
| United Therapeutics Corporation | 885.1 Million USD | 69.229% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -1089.488% |
| Solid Biosciences Inc. | 104.31 Million USD | -161.091% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -732.246% |
| Immuneering Corporation | 58.41 Million USD | -366.262% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -5250.577% |
| Silo Pharma, Inc. | 3.92 Million USD | -6844.595% |
| Belite Bio, Inc | 31.66 Million USD | -760.039% |
| XOMA Corporation | 46.46 Million USD | -486.18% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -303.193% |
| Bionomics Limited | 17.89 Billion USD | 98.478% |
| Apogee Therapeutics, Inc. | 93 Million USD | -192.848% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 863.332% |
| uniQure N.V. | 285.08 Million USD | 4.465% |
| Cassava Sciences, Inc. | 105.95 Million USD | -157.045% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3625.764% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -40.241% |
| Forte Biosciences, Inc. | 32.47 Million USD | -738.615% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -3177.952% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -826.542% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4796.746% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1816.657% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2963.978% |
| Altimmune, Inc. | 30.55 Million USD | -791.337% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 36.313% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 863.332% |
| Compugen Ltd. | 43.97 Million USD | -519.401% |
| Peak Bio, Inc. | 1249.13 USD | -21803635.4% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -267.454% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1116.857% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -11.994% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -854.199% |
| Zura Bio Limited | 62.63 Million USD | -334.811% |
| PolyPid Ltd. | 21.04 Million USD | -1194.165% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1573.366% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -854.199% |
| Instil Bio, Inc. | 85.78 Million USD | -217.488% |
| argenx SE | 1.53 Billion USD | 82.24% |
| Immunome, Inc. | 122.82 Million USD | -121.753% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -461.874% |
| Verona Pharma plc | 67.15 Million USD | -305.587% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -952.181% |
| Shattuck Labs, Inc. | 93.61 Million USD | -190.936% |
| CervoMed Inc. | 14.95 Million USD | -1720.84% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -285.213% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -3087.699% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -434.033% |
| Moolec Science SA | 52.75 Million USD | -416.311% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1555.823% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -105.467% |
| AnaptysBio, Inc. | 181.56 Million USD | -50.003% |
| Design Therapeutics, Inc. | 78.19 Million USD | -248.327% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -212.907% |
| NeurAxis, Inc. | 8.82 Million USD | -2987.528% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -2064.14% |
| Lumos Pharma, Inc. | 38.66 Million USD | -604.402% |
| Achilles Therapeutics plc | 75.25 Million USD | -261.912% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -952.181% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1920.827% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -927.668% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -9186.0% |
| Nutriband Inc. | 5.73 Million USD | -4649.835% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -145.854% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -389.384% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -435.303% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -312.044% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -403.218% |
| Palisade Bio, Inc. | 13.32 Million USD | -1944.722% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -499.786% |
| Beam Therapeutics Inc. | 554.19 Million USD | 50.855% |
| Neurogene Inc. | 55.58 Million USD | -390.001% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -9.605% |
| AEON Biopharma, Inc. | 48.42 Million USD | -462.384% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -181.622% |
| Sesen Bio, Inc. | 78.38 Million USD | -247.478% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -226.063% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -2063.814% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 39.609% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -209.884% |
| Athira Pharma, Inc. | 125.46 Million USD | -117.076% |
| Vaccinex, Inc. | 23.45 Million USD | -1061.19% |
| HCW Biologics Inc. | 21.02 Million USD | -1195.241% |
| XOMA Corporation | 46.46 Million USD | -486.18% |
| Nektar Therapeutics | 190.9 Million USD | -42.668% |
| Arvinas, Inc. | 480 Million USD | 43.259% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -11877.159% |
| Merus N.V. | 200.49 Million USD | -35.843% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -163.516% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -686.704% |
| Rezolute, Inc. | 70.38 Million USD | -286.942% |
| Clene Inc. | 41.07 Million USD | -563.105% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1562.896% |
| BeyondSpring Inc. | 24.86 Million USD | -995.343% |
| Synlogic, Inc. | 58.53 Million USD | -365.313% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1422.228% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -5963.157% |
| Peak Bio, Inc. | 1249.13 USD | -21803635.4% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -350.579% |
| Krystal Biotech, Inc. | 160.42 Million USD | -69.771% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -0.638% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 21.745% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -12528.215% |
| MannKind Corporation | 125.59 Million USD | -116.85% |
| Ikena Oncology, Inc. | 84.57 Million USD | -222.023% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -2723.23% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -203.966% |
| Gossamer Bio, Inc. | 183.75 Million USD | -48.214% |
| CohBar, Inc. | 12.38 Million USD | -2098.502% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -436.939% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -887.445% |
| Legend Biotech Corporation | 583.14 Million USD | 53.295% |
| Mural Oncology plc | 192.07 Million USD | -41.8% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -305.613% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1586.915% |
| Disc Medicine, Inc. | 91.12 Million USD | -198.883% |
| Champions Oncology, Inc. | 28.11 Million USD | -868.897% |
| REGENXBIO Inc. | 321.15 Million USD | 15.195% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -4980.118% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -388.48% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -599.057% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -138.164% |
| Vaxart, Inc. | 90.72 Million USD | -200.197% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -3096.675% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -536.436% |
| Cellectis S.A. | 97.32 Million USD | -179.857% |
| Longeveron Inc. | 21.25 Million USD | -1181.68% |
| Repare Therapeutics Inc. | 167.35 Million USD | -62.74% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 79.986% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -260.046% |
| Revolution Medicines, Inc. | 498.76 Million USD | 45.394% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -3994.363% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -519.641% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -265.139% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -291.121% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -2362.541% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 94.296% |
| Denali Therapeutics Inc. | 527.23 Million USD | 48.342% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -3046.212% |
| Veru Inc. | 101.34 Million USD | -168.734% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -1063.571% |
| Cingulate Inc. | 22.75 Million USD | -1096.69% |
| Passage Bio, Inc. | 108.38 Million USD | -151.277% |
| Context Therapeutics Inc. | 25.07 Million USD | -986.273% |
| Exicure, Inc. | 14.07 Million USD | -1834.903% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -32.171% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -528.985% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -2867.728% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -7.871% |
| Nuvalent, Inc. | 149.49 Million USD | -82.188% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -3276.228% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -162.766% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1169.789% |
| OmniAb, Inc. | 83.89 Million USD | -224.64% |
| Anew Medical, Inc. | 1.3 Million USD | -20836.994% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -731.269% |
| Lipocine Inc. | 15.08 Million USD | -1706.064% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -297.526% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -257.649% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -575.584% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -137.156% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1116.749% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 58.991% |
| Ocugen, Inc. | 71.56 Million USD | -280.562% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -190.155% |
| Q32 Bio Inc. | 92.68 Million USD | -193.868% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -1186.28% |
| Alumis Inc. Common Stock | 158.17 Million USD | -72.188% |
| Equillium, Inc. | 50.6 Million USD | -438.191% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -336.428% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1858.62% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1343.708% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -480.088% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -151.099% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -2097.716% |
| Dominari Holdings Inc. | 23.83 Million USD | -1042.677% |
| Edesa Biotech, Inc. | 9.22 Million USD | -2853.097% |
| vTv Therapeutics Inc. | 11.9 Million USD | -2187.369% |
| Bio-Techne Corporation | 563.03 Million USD | 51.627% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 33.377% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -1.34% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -105.899% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1789.924% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -66.38% |
| Nkarta, Inc. | 131.65 Million USD | -106.88% |
| BioCardia, Inc. | 12.12 Million USD | -2146.985% |
| Iterum Therapeutics plc | 47.46 Million USD | -473.77% |